Overview of pharmaceutical manufacturing capabilities in India focused on specialized oncology formulations, including liposomal doxorubicin (20 mg). Indian facilities adhere to standard cGMP, WHO-GMP, and international regulatory compliances to provide consistent, scalable bulk production and contract manufacturing services for healthcare supply chains. https://unitedbiotechindia.com/products/